Outcomes of curative nephrectomy against renal cell carcinoma based on a central pathological review of 914 specimens from the era of cytokine treatment

被引:5
作者
Ito, Noriyuki [1 ]
Kojima, Shinsuke [2 ]
Teramukai, Satoshi [3 ]
Mikami, Yoshiki [4 ]
Ogawa, Osamu [5 ]
Kamba, Tomomi [5 ]
机构
[1] Nishi Kobe Med Ctr, Dept Urol, Kobe, Hyogo 6512273, Japan
[2] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan
[3] Kyoto Prefectural Univ Med, Dept Biostat, Grad Sch Med Sci, Kyoto, Japan
[4] Kumamoto Univ Hosp, Dept Diagnost Pathol, Kumamoto, Japan
[5] Kyoto Univ, Dept Urol, Grad Sch Med, Kyoto, Japan
关键词
Central pathology; Cytokine; Histological subtypes; Prognostic factors; Renal cell carcinoma; HISTOLOGIC SUBTYPES; RADICAL NEPHRECTOMY; SURVIVAL; IMPACT; CLASSIFICATION; FEATURES; CANCER; GENDER;
D O I
10.1007/s10147-015-0840-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to determine the state of modern practice with regard to renal cell carcinoma (RCC) outcomes and to assess the effects on survival of such clinical and pathological factors such as histological subtype (HS) and nuclear grade by conducting a central pathological review based on the current World Health Organization classification and the staging system of the American Joint Committee on Cancer/Union for International Cancer Control. We collected glass slides and clinical data sets for 914 cases of RCC treated with curative nephrectomy from 1995 to 2000. Overall (OS), cancer-specific (CSS), and relapse-free (RFS) survival were compared for HS and nuclear grades determined by a central pathology review board comprising 5 board-certified pathologists, pathological staging, and a variety of clinical factors. The 5 and 7-year CSS in this study were 96 and 93 %, respectively, values superior to those reported in Western countries. Concordance between the original and reviewed HS and nuclear grades were 90.9 and 21.1 %, respectively. HS correlated with OS (P = 0.043) but was not an independent prognostic factor in the multivariate analysis (P = 0.820). Tumor size, Fuhrman grade, and infiltration type were common independent prognostic factors for OS, CSS, and RFS. This study revealed RCC outcomes in the era of cytokine treatment for metastasis. Central pathological review is an essential component of a multicenter study with long-term follow-up. Tumor size, Fuhrman grade, and infiltration type had much greater effects than HS on survival after curative nephrectomy.
引用
收藏
页码:1161 / 1170
页数:10
相关论文
共 50 条
  • [21] Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy
    Lee, Chunwoo
    You, Dalsan
    Yoo, Sangjun
    Song, Cheryn
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    Kim, Choung-Soo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (07) : 1651 - 1657
  • [22] Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma
    Bhindi, Bimal
    Abel, E. Jason
    Albiges, Laurence
    Bensalah, Karim
    Boorjian, Stephen A.
    Daneshmand, Siamak
    Karam, Jose A.
    Mason, Ross J.
    Powles, Thomas
    Bex, Axel
    EUROPEAN UROLOGY, 2019, 75 (01) : 111 - 128
  • [23] Lessons from histopathologic examination of nephrectomy specimens in patients with tuberous sclerosis complex: cysts, angiomyolipomas, and renal cell carcinoma
    Gupta, Sounak
    Stanton, Melissa L.
    Reynolds, Jordan P.
    Whaley, Rumeal D.
    Herrera-Hernandez, Loren
    Jimenez, Rafael E.
    Cheville, John C.
    HUMAN PATHOLOGY, 2022, 129 : 123 - 139
  • [24] Outcomes of pathologic stage T3a renal cell carcinoma up-staged from small renal tumor: emphasis on partial nephrectomy
    Lee, Hakmin
    Lee, Minseung
    Lee, Sang Eun
    Byun, Seok-Soo
    Kim, Hyeon Hoe
    Kwak, Cheol
    Hong, Sung Kyu
    BMC CANCER, 2018, 18
  • [25] Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies
    Sankin, Alexander
    Hakimi, A. Ari
    Hsieh, James J.
    Molina, Ana M.
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [26] The role of sarcopenia in treatment-related outcomes in patients with renal cell carcinoma: A systematic review and meta-analysis
    Li Yuxuan
    Li Junchao
    Liu Wenya
    MEDICINE, 2022, 101 (43) : E31332
  • [27] Biological sex disparity in survival outcomes following treatment for renal cell carcinoma: A systematic review and meta-analysis
    Nkemjika, Stanley
    Tokede, Oluwatosin
    Okosun, Ike S.
    Jadotte, Yuri
    Pigott, Therese
    CANCER EPIDEMIOLOGY, 2023, 86
  • [28] Oncologic Outcomes of Renal Cell Carcinoma Patients Undergoing Radical Nephrectomy and Venous Thrombectomy: Prospective Follow-Up from a Single Center
    Zhang, Yu
    Tian, XiaoJun
    Bi, Hai
    Hong, Peng
    Liu, Zhuo
    Yan, Ye
    Liu, Cheng
    Ma, LuLin
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [29] Cytoreductive nephrectomy for metastatic renal cell carcinoma: A population-based analysis of perioperative outcomes according to clinical stage
    Takagi, Toshio
    Sugihara, Toru
    Yasunaga, Hideo
    Horiguchi, Hiromasa
    Fushimi, Kiyohide
    Kondo, Tsunenori
    Homma, Yukio
    Tanabe, Kazunari
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (08) : 770 - 775
  • [30] Contemporary Trends in Nephrectomy for Renal Cell Carcinoma in the United States: Results From a Population Based Cohort
    Kim, Simon P.
    Shah, Nilay D.
    Weight, Christopher J.
    Thompson, R. Houston
    Moriarty, James P.
    Shippee, Nathan D.
    Costello, Brian A.
    Boorjian, Stephen A.
    Leibovich, Bradley C.
    JOURNAL OF UROLOGY, 2011, 186 (05) : 1779 - 1785